
Opinion|Videos|June 11, 2024
Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming
Key opinion leaders navigate barriers to optimal care for patients receiving treatment for PNH.
Advertisement
Video content above is prompted by the following:
- What challenges are health care providers commonly faced with regarding the diagnosis and management of paroxysmal nocturnal hemoglobinuria (PNH), given the rarity of the disease and the complexity of its pathophysiology?
- How are electronic health record systems and other health information technology solutions being utilized to aid in the identification of patients with PNH, including those with inadequately controlled disease?
- Please describe the clinical impact and progression of PNH, focusing on the symptoms patients might experience prior to diagnosis, as well as potential complications and comorbidities that may develop over time.
Advertisement
Related to this article

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
Emerging Threats to Cell and Gene Therapy Access
4
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
5

